SCHEMBL19686925

SCHEMBL19686925

CC(C)C(=O)NCc1cc(NC2CCC(F)(F)CC2)nc(-n2ccc(CF)n2)c1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDH1 O75874 5/20 0.34
F2 P00734 2/20 0.34
F11 P03951 2/20 0.34
SMO Q99835 1/20 0.32
ERCC1 P07992 1/20 0.32
ERCC4 Q92889 1/20 0.32
METTL3 Q86U44 1/20 0.32
NAPEPLD Q6IQ20 1/20 0.32
PTGES O14684 5/20 0.31
F10 P00742 1/20 0.31
PRSS1 P07477 1/20 0.31
PRSS2 P07478 1/20 0.31
F7 P08709 1/20 0.31
PRSS3 P35030 1/20 0.31
MAPK1 P28482 1/20 0.31
PRKAB2 O43741 1/20 0.31
PRKAG1 P54619 1/20 0.31
PRKAA2 P54646 1/20 0.31
PRKAA1 Q13131 1/20 0.31
PRKAG3 Q9UGI9 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21143975 0.94 IDH1 (0.34) IDH1F2F11SMOERCC1
SCHEMBL31127100 0.94 IDH1 (0.34) IDH1F2F11SMOERCC1
SCHEMBL19686343 0.91 IDH1 (0.35) IDH1F2F11METTL3NAPEPLD
SCHEMBL21143958 0.90 IDH1 (0.35) IDH1F2F11METTL3NAPEPLD
SCHEMBL21144273 0.90 IDH1 (0.32) IDH1F2F11SMOERCC1
SCHEMBL19686404 0.90 IDH1 (0.34) IDH1F2F11METTL3NAPEPLD
SCHEMBL19686411 0.90 IDH1 (0.35) IDH1F2F11SMOERCC1
SCHEMBL21144021 0.85 CCNA2 (0.36) IDH1F2F11METTL3NAPEPLD
SCHEMBL21143754 0.84 IDH1 (0.36) IDH1F2F11METTL3NAPEPLD
SCHEMBL21166293 0.83 IDH1 (0.34) IDH1F2F11METTL3NAPEPLD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240317705-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2024-09-26 US disclosed
US-10774064-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-09-15 US disclosed
US-10774064-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-09-15 US disclosed
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2019-07-18 US disclosed
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2019-07-18 US disclosed
WO-2017139697-A9 BACTERIA ENGINEERED TO TREAT DISEASES ASSOCIATED WITH HYPERAMMONEMIA SYNLOGIC, INC. (US) 2017-12-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240317705-A1 POTASSIUM CHANNEL MODULATORS KCNJ11, KCNJ2, KCNJ1 IDH1 3017/4885F2 4167/4885F11 3066/4885
US-10774064-B2 Potassium channel modulators KCNJ11, KCNJ2, KCNJ1 IDH1 3017/4885F2 4167/4885F11 3066/4885
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS KCNJ11, KCNJ2, KCNJ1 IDH1 3017/4885F2 4167/4885F11 3066/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.